Mumbai, Feb. 12 -- The company, along with its wholly owned subsidiary Zydus Pharmaceuticals USA, has entered into a settlement that concludes all ongoing patent litigations with Astellas concerning Myrbetriq and Mirabegron.

Under the terms of the agreement, Zydus will pay Astellas an aggregate amount of $120 million. In addition, the company will pay a prepaid per-unit licensing fee on sales of its generic Mirabegron in the US from the date of the settlement until September 2027. Other terms of the agreement remain confidential. The settlement enables Zydus to continue marketing its generic Mirabegron product in the US market.

In April 2025, Zydus had informed exchanges that the United States District Court for the District of Delaware...